| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8443815 | European Journal of Cancer | 2014 | 7 Pages |
Abstract
Lacking randomised trials in this specific molecular subgroup, FOLFOXIRI plus bevacizumab might be a reasonable option for the first-line treatment of BRAF mutant mCRC patients.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
F. Loupakis, C. Cremolini, L. Salvatore, G. Masi, E. Sensi, M. Schirripa, A. Michelucci, E. Pfanner, I. Brunetti, C. Lupi, C. Antoniotti, F. Bergamo, S. Lonardi, V. Zagonel, P. Simi, G. Fontanini, A. Falcone,